Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Region Västerbotten | OTHER_GOV |
| The Swedish Brain Foundation (Hjärnfonden) | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
We live in an aging population and a third of the older population has a gait disorder that may cause institutionalization, and increased mortality. Sixteen percent of them have a slow, unsteady, neurological gait disorder, called Higher-Level Gait Disorder (HLGD). A known cause of HLGD is Idiopathic Normal Pressure Hydrocephalus (INPH), which is a treatable neurological disease. More than half of individuals with HLGD meet the diagnostic criteria for INPH as they have wide brain ventricles on MRI images of the brain, but far from all of these are in contact with the healthcare system. Possibly, HLGD without wide brain ventricles and where no other known explanation for the symptom is found could be a variant of or a precursor to INPH.
Gait disorder is common among older people and can lead to falls and reduced quality of life. Complications after falls contribute to both increased mortality and increased costs in society. Therefore, it is important to have a solid knowledge of different types of gait disorders and how they can be treated. Our research will contribute with information about how HLGD affects the individual and how affected individuals can be investigated and helped.
The disease mechanisms behind INPH and often behind HLGD are unknown. It is also unknown how often older individuals are affected by HLGD and how high the mortality is for those affected. It is likely that the incidence of HLGD is high and that it is linked to an increased mortality. It is also likely that the disease mechanism behind the symptom is the same as that of INPH and that HLGD can be detected with the help of brain imaging.
In this epidemiological cohort study, we want to answer the following overarching questions:
What is the incidence and mortality of HLGD and INPH? Can HLGD be predicted using biomarkers and what disease mechanism causes HLGD?
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Higher-level gait disorder | Individuals who in our previous study had a higher-level gait disorder | ||
| Other gait disorder/No gait disorder | Individuals who did not have a higher-level gait disorder during their visit in our pervious study |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Mortality | 6 years | |
| 6 year incidence of Higher-Level Gait Disorder and Idiopathic Normal Pressure Hydrocephalus | Number of individuals that have developed a Higher-Level Gait Disorder and Idiopathic Normal Pressure Hydrocephalus since their last visit to us, in our previous study VESPR. | 6 years |
| Measure | Description | Time Frame |
|---|---|---|
| MRI Biomarkers for prediction of HLGD | MRI biomarkers commonly used in hydrocephalus diagnostics such as Evans Index, Callosal Angle and DESH will be evaluated for prediction of HLGD development. New biomarkers will also be investigated as potential new diagnostic tools. | 6 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
In the VeSPR study, a questionnaire about gait problems was sent to 6467 randomly selected individuals aged 65-84 years in Umeå. All with self-perceived gait problems (n=1510) and 513 controls without self-perceived gait problems were invited to a physical examination by a physician as well as clinical examinations of gait and balance, cognition and comorbidity. Of these, 1047 participated in clinical examinations (798 with gait disorders and 249 controls), 909 of them had a subsequent MRI of the brain and 98 had a computed tomography (CT) scan. With a theoretical constant mortality rate of 2.3%/year (Swedish official statistics on mortality in the age-group), there is a remaining population of 910 individuals from the previous study to invite to the 6-year follow-up. We expect about half of these will choose to participate, resulting in approximately 450 participants.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jenny Larsson, MD, PhD | Umeå University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Umeå University Hospital | Umeå | Sweden |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Blood samples
| ID | Term |
|---|---|
| D020233 | Gait Disorders, Neurologic |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided